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Research
AbstrACt
Objective To develop and validate a new scale to assess 
treatment burden (the effort of looking after one’s health) 
for patients with multimorbidity.
Design Mixed-methods.
setting UK primary care.
Participants Content of the Multimorbidity Treatment 
Burden Questionnaire (MTBQ) was based on a literature 
review and views from a patient and public involvement 
group. Face validity was assessed through cognitive 
interviews. The scale was piloted and the final version was 
tested in 1546 adults with multimorbidity (mean age 71 
years) who took part in the 3D Study, a cluster randomised 
controlled trial. For each question, we examined the 
proportion of missing data and the distribution of 
responses. Factor analysis, Cronbach’s alpha, Spearman’s 
rank correlations and longitudinal regression assessed 
dimensional structure, internal consistency reliability, 
construct validity and responsiveness, respectively. 
We assessed interpretability by grouping the global 
MTBQ scores into zero and tertiles (>0) and comparing 
participant characteristics across these categories. 
results Cognitive interviews found good acceptability 
and content validity. Factor analysis supported a one-factor 
solution. Cronbach’s alpha was 0.83, indicating internal 
consistency reliability. The MTBQ score had a positive 
association with a comparator treatment burden scale (r
s 
0.58, P<0.0001) and with self-reported disease burden (rs 
0.43, P<0.0001), and a negative association with quality 
of life (rs−0.36, P<0.0001) and self-rated health (rs−0.36, 
P<0.0001). Female participants, younger participants and 
participants with mental health conditions were more likely 
to have high treatment burden scores. Changes in MTBQ 
score over 9-month follow-up were associated, as expected, 
with changes in measures of quality of life (EuroQol five 
dimensions, five level questionnaire) and patient-centred 
care (Patient Assessment of Chronic Illness Care).
Conclusion The MTBQ is a 10-item measure of 
treatment burden for patients with multimorbidity that 
has demonstrated good content validity, construct validity, 
reliability and responsiveness. It is a useful research tool for 
assessing the impact of interventions on treatment burden.
trial registration number ISRCTN06180958.
IntrODuCtIOn 
Treatment burden is a patient’s perception 
of the effort required to self-manage their 
medical conditions and the impact that this 
has on their general well-being.1 This includes 
complex medication regimens, coordinating 
healthcare appointments, making lifestyle 
changes and self-monitoring.
This is particularly relevant to patients with 
multimorbidity (having multiple long-term 
conditions). Associated with the ageing popu-
lation, multimorbidity has become the norm, 
affecting over two-thirds of adults attending 
general practice.2 Current health policy 
envisages greater support for patients to self-
manage their chronic medical conditions. 
However, the time and energy this requires of 
patients can be overwhelming.3
In order to understand the impact of treat-
ment burden, and particularly to assess the 
effects of interventions that might increase 
or decrease burden, a valid patient-re-
ported outcome measure (PROM) is essen-
tial. There are four existing PROMs that 
measure aspects of treatment burden for 
patients with multimorbidity,4–8 all of which 
have important limitations. The 13-question 
Treatment Burden Questionnaire (TBQ) 
was originally developed in French, and 
subsequently a revised 15-question English 
version was tested.4 5 Some of the content is 
healthcare system-specific and the wording 
strengths and limitations of this study
 ► A concise, simply worded measure based on an evi-
dence-based framework to include all the important 
aspects of treatment burden was developed and 
validated.
 ► The measure was comprehensively tested using in-
ternational standards for validating questionnaires.
 ► The measure was validated in 1546 mostly elderly 
patients with three or more long-term conditions.
 ► Study participants were recruited into a trial, which 
may limit generalisability.
 ► High floor effects were found similar to other exist-
ing treatment burden questionnaires.
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is relatively complex, perhaps reflecting the fact that the 
English version was tested in a relatively young and highly 
educated population of volunteers recruited from the 
‘Patients like me’ website (mean age 51 years, 78% with 
college education), not all of whom had multimorbidity.4 
The Patient Experience with Treatment and Self-man-
agement (PETS) PROM was recently developed in the 
USA and includes 48 questions grouped under nine sepa-
rate domains of treatment burden.8 While this measure 
is comprehensive, its length is a limitation. The Multi-
morbidity Illness Perceptions Scale (MULTIPLes) was 
developed and validated in elderly patients (mean age 
70 years) with multimorbidity and includes a six-question 
treatment burden subscale and a three-question activity 
limitation subscale.7 This measure is brief but omits 
several important aspects of treatment burden. Similarly, 
the 11-question Healthcare Task Difficulty (HCTD) ques-
tionnaire was designed to measure only one aspect of 
treatment burden.6
The purpose of this study was to develop and validate 
a new concise measure of treatment burden for patients 
with multimorbidity.
MethODs
study setting
This questionnaire was developed and validated as part of 
the 3D Study, a multicentre, cluster randomised control 
trial that aims to improve the management of patients 
with multimorbidity within primary care.9 Participants 
aged 18 years or older with three or more of the long-
term conditions included in the 2014 UK Quality and 
Outcomes Framework were recruited from 33 general 
practices in three areas of the UK.
Development of the questionnaire
We reviewed the literature on the concept and measure-
ment of treatment burden in multimorbidity using 
PubMed in July 2014. We identified a number of rele-
vant qualitative studies10–12 and three relevant existing 
PROMs that were not specific to a particular medical 
condition. These were the TBQ,4 5 the MULTIPLes7 
and the HCTD questionnaires.6 A further measure, the 
PETS scale, was published later.8 We identified relevant 
domains for the PROM by reviewing the three existing 
PROMs against a framework of treatment burden which 
had been developed following qualitative interviews and 
focus groups.1 We then sought the views from a patient 
and public involvement (PPI) group of eight patients 
with multimorbidity formed for the purpose of the 3D 
Study, discussing the concept of treatment burden, the 
existing measures, the treatment burden framework 
and the domains of treatment burden to be included 
in the questionnaire. We then developed a draft ques-
tionnaire with 12 questions and undertook two rounds 
of cognitive interviews with eight PPI group members to 
improve the face and content validity of the scale (online 
supplementary appendix A).13 Participants were asked 
to ‘think aloud’13 as they completed the questionnaire 
commenting on the reasoning behind their ratings; 
and perceived question meaning, the layout, title, intro-
duction and general wording. They also gave their own 
examples of treatment burden and reflected on whether 
these would be captured by the questionnaire. Modifi-
cations to the questionnaire were made between the 
two rounds and an additional question was added about 
accessing healthcare during the evenings and weekends 
(see the Results section). Following written consent, 
the interviews were audio-taped and field notes were 
taken. The second round of cognitive interviews led to 
only minor changes to the questionnaire with no new 
insights emerging. A debriefing meeting was held with 
PPI members and final changes to the 13-question ques-
tionnaire were made.
recruitment, data collection and measures
Data were collected in two related studies, the cross-sec-
tional 3D pilot study and the longitudinal main 3D Study, 
a cluster randomised controlled trial. The 13 candidate 
questions were included in a questionnaire, named 
the Multimorbidity Treatment Burden Questionnaire 
(MTBQ). Sociodemographic information (see table 1) 
was collected at baseline in both the pilot and main 
studies. Details of participants’ medical conditions were 
collected from their family practice computer records. 
Measures of health-related quality of life (EQ-5D-5L),14 
self-rated health (single question item), self-reported 
disease burden (Bayliss)15 and patient-centred care 
(Patient Assessment of Chronic Illness Care (PACIC))16 
were collected at baseline and 9 months in both the 
pilot and main 3D studies. Following a review of existing 
measures and discussion with the PPI group, the HCTD6 
questionnaire was included in the pilot study question-
naire as the best comparator for the MTBQ. A key reason 
for choosing this measure was the simple wording and 
brevity. This was felt to be important because many of the 
participants of the 3D Study were older people and some 
had low literacy levels.
The questionnaire was sent to participants by post. For 
non-responders, a reminder letter was sent 10–14 days 
later, and a second reminder phone call was made 10–14 
days after this.
Analysis
Data were analysed using STATA V.14. We generated 
descriptive statistics of participant characteristics for the 
pilot and main studies. The pilot study data were used to 
test the prespecified hypothesis of a positive association 
between global MTBQ score and HCTD score. The main 
study data were used for the remainder of the analysis.
We tested the psychometric properties of the question-
naire against the minimum standards set out by the Inter-
national Society for Quality of Life Research (ISOQOL).17 
The analysis plan and results are described in relation to 
ISOQOL’s six recommended standards.
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1. Conceptual and measurement model
Conceptual framework
See the ‘Development of the questionnaire’ section.
Question properties
To assess the properties of the questions, we examined 
the proportion of missing data and ‘does not apply’ 
responses and the distribution of responses. Responses of 
‘not difficult’ or ‘does not apply’ were scored as 0. Floor 
and ceiling effects of the MTBQ were compared with the 
HCTD.6 Questions with a proportion of ‘does not apply’ 
responses greater than 40% were removed and excluded 
from the analysis.
Dimensionality
To examine the dimensionality of the scale, we performed 
factor analysis. This is a statistical technique used to 
reduce a larger number of items into a smaller number 
of common factors that reflect shared variance.18 Items 
that share a lot of variance should have high ‘loadings’ 
(correlation between the item and the factor) and low 
uniqueness (variance that is unique to the item, not 
common to the factor). Loading of at least 0.4 and 
uniqueness of less than 0.6 are acceptable.19 The number 
of factors extracted was decided by a combination of 
Kaiser’s rule (eigenvalues greater than 1),20 the scree 
plot18 and by interpretability of domains.
2. Reliability
To test internal consistency reliability, we examined the 
interitem correlation matrix and calculated Cronbach’s 
alpha, a measure of consistency between the items in a 
scale. Interitem correlations between 0.2 and 0.4 were 
deemed ideal.21 A Cronbach’s alpha of 0.7–0.9 was 
acceptable.22
3. Validity
Content validity
The content validity of the questionnaire was tested itera-
tively using cognitive interviews (see the ‘Development of 
the questionnaire’ section).
Construct validity
Each question was scored as follows: 0 (not difficult/
does not apply), 1 (a little difficult), 2 (quite difficult), 
3 (very difficult) and 4 (extremely difficult). Participants 
were excluded if more than 50% of their responses were 
missing. To calculate a global score, each participant’s 
average score was calculated from the questions answered 
and multiplied by 25 to give a score from 0 to 100.
Construct validity was examined by testing five prespeci-
fied hypotheses: first, a positive association between global 
MTBQ score and global HCTD score6; second, a negative 
association between global MTBQ score and health-re-
lated quality of life (EQ-5D-5L)14; third, a positive asso-
ciation between global MTBQ score and self-reported 
disease burden score15; fourth, a positive association 
between global MTBQ score and number of self-reported 
comorbidities15; and fifth, a negative association between 
global MTBQ and self-rated health (single question 
item). We applied Spearman’s rank correlation to test 
these hypotheses.
Responsiveness
According to the ISOQOL guidelines, responsiveness 
to change should be assessed.17 Due to the non-normal 
distribution of the global MTBQ score, standard methods 
to assess responsiveness to change such as calculating an 
effect size22 were not possible. We therefore tested the 
responsiveness of the global MTBQ score by assessing 
whether changes over time in measures of quality of life 
(EQ-5D-5L)14 and patient-centred care (PACIC)16 were 
inversely associated with changes in MTBQ as anticipated. 
We used a linear regression model of the standardised 
change in quality of life (EQ-5D-5L) score between base-
line and 9 months on the standardised change in MTBQ 
between baseline and 9 months. These standardised 
change scores were calculated at the participant level by 
dividing the individual difference in 9-month and base-
line MTBQ (or EQ-5D-5L) score by the SD of the overall 
MTBQ (or EQ-5D-5L) change score for all individuals. 
We then further adjusted this linear regression model in a 
subsequent analysis by age, gender, number of long-term 
conditions and individual participant deprivation level. 
All participants who died prior to the 9-month follow-up 
were given an EQ-5D-5L follow-up score of 0.
We then used the same model for MTBQ specified as 
above but included the standardised change in PACIC 
scores between baseline and 9-month follow-up, defined 
as previously, and subsequently further adjusted this 
model by the additional covariates as specified.
4. Interpretability of scores
The distribution of global MTBQ scores was examined 
and compared with the distribution of HCTD6 scores.
We assessed interpretability of the questionnaire by 
grouping the global MTBQ scores greater than 0 into 
tertiles. Four categories were generated: no burden (score 
0), low burden (score <10), medium burden (10–22) and 
high burden (≥22). Participant characteristics and key 
outcome variables, including EQ-5D-5L,14 Bayliss disease 
burden score15 and self-rated health, were compared 
across these four categories. To test for associations 
between treatment burden score category and participant 
characteristics, we performed ordinal logistic regression 
of MTBQ group (four treatment burden categories) on 
each participant characteristic. We then further adjusted 
these ordinal logistic regression models by age, gender, 
number of comorbidities, age left full-time education and 
individual deprivation score.
5. Translation
Not applicable.
6. Demands on patient respondents and investigators
The effort required of patient respondents to complete 
the questionnaire was assessed during the cognitive 
interviews, and by reviewing the proportion of missing 
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Table 1 Participant characteristics (main study n=1546, 
pilot study n=143)
Pilot study
n/N* (%)
Main study
n/N* (%)
Mean age (SD) 74 (10) 71 (12)
Age (years) 
  ≤50 3 (2) 79 (5)
  51–60 9 (6) 196 (13)
  61–70 27 (19) 420 (27)
  71–80 67 (47) 510 (33)
  81–90 33 (23) 315 (20)
  ≥90 4 (3) 26 (2)
Gender 
  Male 65 (45) 763 (49)
Number of 
comorbidities 
  3 109 (76) 1234 (80)
  4 23 (16) 277 (18)
  5 10 (7) 31 (2)
  6 1 (<1) 4 (<1)
Comorbidities* 
  Cardiovascular 
disease
138 (97) 1445 (97)
  Stroke/Transient 
ischaemic attack
35 (25) 527 (34)
  Diabetes 63 (44) 811 (52)
  Chronic kidney 
disease
83 (58) 464 (30)
  Chronic obstructive 
pulmonary disease 
or asthma
58 (41) 770 (50)
  Epilepsy 6 (4) 76 (5)
  Atrial fibrillation 46 (32) 529 (34)
  Severe mental 
health problems†
2 (1) 66 (4)
  Depression 26 (18) 560 (36)
  Dementia 6 (4) 60 (4)
  Learning disability 3 (2) 14 (1)
  Rheumatoid 
arthritis
9 (6) 103 (7)
  Heart failure 14 (10) 157 (10)
Ethnicity 
  White British 135/136 (99) 1502/1519 (99)
Age left full-time 
education (years) 
  ≤14 22 (15) 154/1541 (10)
  15 or 16 74 (52) 907/1541 (59)
  17 or 18 25 (17) 222/1541 (14)
  ≥19 22 (15) 258/1541 (17)
Employment status 
  Fully retired from 
work 
113/139 (81) 1044/1501 (70) 
Continued
Pilot study
n/N* (%)
Main study
n/N* (%)
Deprivation score 
quartile‡
  England
   Lower quartile 99/143 (69) 445/1079 (41) 
   Middle lower 
quartile 
44/143 (31) 304/1079 (28) 
   Middle upper 
quartile 
0 196/1079 (18) 
   Upper quartile 0 134/1079 (12) 
  Scotland
   Lower quartile 105/467 (22) 
   Middle lower 
quartile 
46/467 (10) 
   Middle upper 
quartile 
156/467 (33) 
   Upper quartile 160/467 (34)
Baseline scores of 
outcome measures 
  Mean HCTD score§ 
(SD, N) 
1.14 (1.7, 143)
  Mean self-reported 
disease burden 
score¶(SD, N) 
19 (12.4, 1458)
  Mean number 
of self-reported 
conditions** (SD, N) 
8 (3.2, 1543)
  Mean quality of life 
score†† (SD, N) 
0.6 (0.3, 1542)
  Mean self-rated 
health score‡‡ 
(SD, N)
2 (0.8, 1523)
  Mean patient- 
centred health 
score§§(SD, N) 
2.5 (1.0, 1232)
*For characteristics where there are no missing data, n is shown; 
for characteristics with missing data n/N is shown. 
†Including schizophrenia and psychotic illness.
‡Individual Index of Multiple Deprivation score, 2010, for England, 
and Scottish Index of Multiple Deprivation score, 2012, for 
Scotland, based on participants’ postcodes. The lower quartile is 
the least deprived and the upper quartile is the most deprived.
§Calculation of global HCTD score: sum of scores where each 
question was scored 0 (no difficulty), 1 (some difficulty) or 2 (a lot 
of difficulty). Minimum score 0, maximum score 16. Missing data 
were scored 0 (not difficult), as suggested by the HCTD authors.6
¶Sum of the weighted scores (each scored 1–5) from the Bayliss 
scale.12 Responses were excluded if participants ticked that they 
had a condition but did not score how much the condition limited 
their daily activity, or if they gave a score without ticking that they 
had the condition.
**Number of self-reported conditions from a list of 27 conditions 
itemised in the Bayliss scale.
 ††EuroQol five dimensions, five level questionnaire (EQ-5D-5L) 
score.11
 ‡‡Single question: ‘In general, would you say your health is poor 
(1), fair (2), good (3), very good (4) or excellent (5)?’
 §§Patient Assessment of Chronic Illness Care score.13
HCTD, Healthcare Task Difficulty.
Table 1 Continued 
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responses. We set out to reduce the demands on investi-
gators by providing clear instructions on how to calculate 
a global MTBQ score, including handling of missing data, 
and how to report and interpret these scores.
ethical approval and data sharing
The study was registered under trial registration number 
ISRCTN06180958 (main trial results yet to be published). 
Data will be available from the University of Bristol 
Research Data Storage Facility after the main results of 
the 3D trial have been published in 2018.
results
Participant characteristics
One hundred and forty-three adults participated in the 
pilot study. From 1546 participants in the main 3D Study 
who completed the main baseline questionnaire, we were 
able to calculate an MTBQ score for 1524 (99%) individ-
uals who completed at least half of the baseline MTBQ 
questions. At 9-month follow-up, 1356 returned the ques-
tionnaire and an MTBQ score could be calculated for 
1299 (96%). The participants were mostly elderly (mean 
age 71 years for the main study), fully retired from work, 
had left school aged 16 years or younger, and 99% were 
white British (table 1). Around two-thirds of participants 
from England lived in areas of low deprivation (low or 
middle lower quartiles), whereas almost two-thirds of 
participants from Scotland lived in areas of high depriva-
tion (middle upper or upper quartiles).
Conceptual and measurement model
Conceptual framework
The framework developed by Eton et al1 describes three 
major themes of treatment burden: the work required to 
look after one’s health (eg, self-monitoring, making life-
style changes); tools and strategies patients use to reduce 
their treatment burden (eg, organising medication); and 
factors that increase burden (eg, poor continuity of care). 
We mapped the three existing treatment burden question-
naires against this framework, and discussed this with the 
PPI group who felt that all of the domains of treatment 
burden identified in the literature should be included in 
the PROM. We had initially considered excluding ques-
tions about costs since healthcare is mostly free under the 
National Health Service, but our PPI group argued that 
they still experienced additional costs from managing 
illness so this domain was retained in the first draft.
Question properties
The proportion of missing data for each question was 
between 1% and 3% (see table 2). Questions 3, 9 and 
10 with a high proportion of ‘does not apply’ responses 
(table 2) were excluded from the main analysis. Since 
these questions might apply to other populations, we 
repeated Cronbach’s alpha including these questions 
in the various combinations (online supplementary 
appendix B). These extra questions may be considered as 
optional depending on the study population. Responses 
were positively skewed and a floor effect was found for 
some questions. However, the MTBQ had fewer floor 
effects than the comparator HCTD (online supplemen-
tary appendix C).
The global MTBQ scores were also skewed with 26% 
of pilot study participants and 22% of main study partic-
ipants scoring 0 (online supplementary appendix D). 
Again, the HCTD had greater floor effects, with 54% of 
participants having a global score of 0.
Dimensionality
Both Kaiser’s ‘eigenvalue greater than one’ rule and 
Cattell’s scree plot criterion suggested a one-factor solu-
tion, and this explained 93% of the common variance. 
Loadings on this factor were uniformly greater than 0.4. 
The factor solution had high uniqueness for some items. 
This can sometimes indicate that the item is not strongly 
related to others,18 but because of the important content 
of these variables (eg, lifestyle changes, collecting medi-
cation), we chose to include them.
Reliability
Questions 1 and 2 have a high interitem correla-
tion of 0.69, and questions 6 and 7 have an interitem 
correlation of 0.62 (online supplementary appendix 
E). Almost all of the other interitem correlations were 
in the ideal range of 0.2–0.4. A decision was made to 
include questions 1 and 2, and 6 and 7, despite the high 
interitem correlation coefficients because it was felt 
these questions were about different aspects of treat-
ment burden. Cronbach’s alpha was 0.83, indicating a 
high level of internal reliability. Including the optional 
questions (questions 3, 9 and 10) in various combina-
tions, Cronbach’s alpha ranged from 0.82 to 0.84, again 
demonstrating good internal consistency (see online 
supplementary appendix B).
Validity
Face and content validity
Participants from the PPI group commented that the 
wording was clear and easy to understand. One partic-
ipant felt that accessing healthcare outside of usual 
general practitioner (GP) opening hours caused signif-
icant treatment burden for him. In response to this, we 
added a question about difficulty getting healthcare in 
the evenings and weekends (question 10). The remaining 
participants commented that the important areas of treat-
ment burden were covered by the questionnaire.
Construct validity
As predicted, the global MTBQ score had a positive 
association with the comparator HCTD scale6 (rs 0.58, 
P<0.0001), the Bayliss disease burden scale12 (rs 0.43, 
P<0.0001) and the number of self-reported comorbidities 
(rs 0.32, P<0.0001), and a negative association with the 
quality of life scale14 (rs−0.36, P<0.0001) and self-rated 
health (rs−0.36, P<0.0001) (table 3). This provides good 
evidence on the construct validity of the scale.
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Responsiveness
Regression analysis found that for every 1 SD (ie, 0.17) 
increase in EQ-5D-5L score14 between baseline and 
9-month follow-up, the MTBQ score at follow-up was 
reduced by 1.7 (regression coefficient −0.14 multiplied by 
an SD change in MTBQ score of 11.9 (95% CI for regres-
sion coefficient −0.19 to −0.08), P<0.0001) (see table 4). 
This association was also seen after further adjusting the 
model for the specified covariates (regression coefficient 
−0.14 (95% CI −0.20 to −0.08), P<0.0001).
The equivalent model for PACIC score16 showed that 
for every 1 SD (ie, 0.86) increase in PACIC score between 
baseline and 9-month follow-up, MTBQ at follow-up was 
reduced by 1.9 (regression coefficient −0.16 multiplied by 
an SD change in MTBQ score of 11.9 (95% CI for regres-
sion coefficient −0.22 to −0.10), P<0.0001). A similar 
decrease was also seen after further adjusting the model 
for the specified covariates (regression coefficient −0.17 
(95% CI −0.23 to −0.11), P<0.0001).
Interpretability of scores
Comparing participants across the four treatment 
burden groups (no burden, low burden, medium 
burden and high burden), female participants; younger 
participants; those with a greater number of long-term 
conditions; participants with depression, dementia 
and severe mental health problems listed on their GP 
records; and participants with worse EQ-5D-5L scores,14 
high disease burden scores12 and poor self-rated health 
were more likely to have a high treatment burden score, 
after adjusting for age, gender, number of comorbidities, 
age left full-time education and individual deprivation 
level (see table 5). There was no convincing association 
between deprivation score and treatment burden score.
Translation
Not applicable.
Demands on patient respondents and investigators
We have reduced the effort required from patient responders 
to complete the questionnaire by developing a short 10-item 
questionnaire with simple wording, fitting on one side of 
A4 paper in size 14 font. Participants who took part in the 
cognitive interviews found this relatively simple to complete, 
and the proportion of missing data was between 1% and 
3%. To reduce demands on investigators, we have provided 
clear instructions on calculating, reporting and interpreting 
global MTBQ scores.
Table 2 Responses to the Multimorbidity Treatment Burden Questionnaire (main study baseline data, n=1546)
Please tell us how much difficulty you have 
with the following: N
Not 
difficult
n (n/N %)
A little 
difficult
n (n/N %)
Quite 
difficult
n (n/N %)
Very 
difficult
n (n/N %)
Extremely 
difficult
n (n/N %)
Does not 
apply
n (n/N %)
1. Taking lots of medications 1518 1083 (71) 257 (17) 104 (7) 25 (2) 20 (1) 29 (2)
2. Remembering how and when to take 
medication
1519 1123 (74) 271 (18) 60 (4) 21 (1) 23 (2) 21 (1)
3. Paying for prescriptions, over the counter 
medication or equipment
1506 312 (21) 17 (1) 18 (1) 4 (<1) 8 (1) 1147 (76)
4. Collecting prescription medication 1514 951 (63) 221 (15) 63 (4) 22 (1) 28 (2) 229 (15)
5. Monitoring your medical conditions (eg, 
checking your blood pressure or blood sugar, 
monitoring your symptoms, etc)
1513 748 (49) 191 (13) 111 (7) 35 (2) 37 (2) 391 (26)
6. Arranging appointments with health 
professionals
1507 765 (51) 321 (21) 210 (14) 81 (5) 66 (4) 64 (4)
7. Seeing lots of different health professionals 1506 642 (43) 309 (21) 192 (13) 85 (6) 68 (5) 210 (14)
8. Attending appointments with health 
professionals (eg, getting time off work, 
arranging transport, etc)
1512 771 (51) 187 (12) 107 (7) 51 (3) 44 (3) 352 (23)
9. Getting health care in the evenings and at 
weekends
1496 311 (21) 156 (10) 184 (12) 106 (7) 121 (8) 618 (41)
10. Getting help from community services (eg, 
physiotherapy, district nurses, etc)
1500 393 (26) 138 (9) 111 (7) 51 (3) 54 (4) 753 (50)
11. Obtaining clear and up-to-date information 
about your condition
1499 794 (53) 263 (18) 179 (12) 62 (4) 47 (3) 154 (10)
12. Making recommended lifestyle changes (eg, 
diet and exercise)
1505 534 (35) 327 (21) 203 (13) 112 (7) 75 (5) 254 (17)
13. Having to rely on help from family and 
friends
1509 675 (45) 213 (14) 140 (9) 59 (4) 70 (5) 352 (23)
Notes: Questions 3, 9 and 10 were excluded from the main analysis due to a high proportion of ‘does not apply’ responses. They are shown 
in italics. As they may be relevant to other populations, they can be considered as optional.
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DIsCussIOn
In this study, we have developed and validated a 10-item 
questionnaire, named the Multimorbidity Treatment 
Burden Questionnaire (MTBQ). The psychometric 
properties of the questionnaire meet the minimum stan-
dards for a PROM set out by ISOQOL,17 demonstrating 
good content validity, internal reliability consistency, 
construct validity and responsiveness. Three additional 
questions, including one question about the cost of 
treatment, had a high proportion of ‘does not apply’ 
responses in this study population and were omitted from 
the main analysis. However, these questions may be rele-
vant to other populations (eg, countries where patients 
pay for prescriptions and healthcare), and the scale 
remained internally consistent and reliable when they 
were included, so they may be considered as optional.
We found that younger patients were more likely to 
report high treatment burden scores and, interestingly, 
Tran’s TBQ found the same phenomenon.5 There are 
several possible explanations for this. First, treatment 
burden may impact more on younger patients because 
they must juggle their appointments or complex medi-
cation regimens alongside having to work or look after 
dependants. Second, younger patients may have different 
expectations of how looking after one’s health might 
impact on their lives and, hence, suffer from a greater 
perceived treatment burden. As expected, we found that 
patients with mental health conditions including depres-
sion and dementia were more likely to have high treatment 
burden scores. Previous studies have reported similar 
findings.6 7 High treatment burden was also associated 
with having a greater number of long-term conditions. No 
individual physical condition was found to be associated 
with high treatment burden. This result differs from both 
the TBQ study, which found an association between treat-
ment burden and diabetes, and the HCTD study, which 
found an association between treatment burden and 
stroke, congestive heart failure and falls.5 6 As expected, 
Table 4 Association between global MTBQ score and (1) quality of life (EQ-5D-5L)11 score and (2) PACIC13 score 
Outcome N*
Linear regression 
coefficient of MTBQ 
standardised change 
score (95% CI) P value N
Adjusted† linear 
regression coefficient 
of MTBQ standardised 
change score (95% CI) P value
EQ-5D-5L 
standardised change 
score
1270 −0.14 (−0.19 to −0.08) <0.0001 1239 −0.14 (−0.20 to −0.08) <0.0001
PACIC standardised 
change score
930 −0.16 (−0.22 to −0.10) <0.0001 914 −0.17 (−0.23 to −0.11) <0.0001
Outcome N‡ SD change in score between baseline and 9-month follow-up
EQ-5D-5L 1344 0.17
PACIC 946 0.86
MTBQ 1285 11.9
Results were from linear regression model of standardised change. 
*This analysis included participants who completed the outcome questionnaire (EQ-5D-5L or PACIC) and the MTBQ questionnaire at baseline 
and 9-month follow-up.
†Linear regression model further adjusted for age, gender, number of comorbidities, age left full-time education and individual deprivation 
score.
‡This analysis included participants who completed the outcome questionnaire (EuroQol five dimensions, five level questionnaire (EQ-5D-5L), 
PACIC or MTBQ) at baseline and 9-month follow-up.
MTBQ, Multimorbidity Treatment Burden Questionnaire; PACIC, Patient Assessment of Chronic Illness Care. 
Table 3 Association between global MTBQ score and 
global HCTD score, self-reported disease burden score, 
quality of life score, number of self-reported conditions and 
self-rated health at baseline
Variable N
Spearman’s 
rank 
correlations (rs) P values
Global HCTD score* 141 0.58 <0.0001
Self-reported disease 
burden score†
1443 0.42 <0.0001
Number of self-
reported conditions‡
1523 0.31 <0.0001
Quality of life score§ 1520 −0.36 <0.0001
Self-rated health¶ 1503 −0.36 <0.0001
*Calculation of global HCTD score: sum of scores where each 
question was scored 0 (no difficulty), 1 (some difficulty) or 2 (a lot 
of difficulty). Minimum score 0, maximum score 16. Missing data 
were scored 0 (not difficult), as suggested by the HCTD authors.6
†Sum of the weighted scores (each scored 1–5) from the Bayliss 
scale.12 Responses were excluded if participants ticked that they 
had a condition but did not score how much the condition limited 
their daily activity, or if they gave a score without ticking that they 
had the condition.
‡Number of self-reported conditions from the Bayliss scale.
§EuroQol five dimensions, five level questionnaire (EQ-5D-5L) 
score.11
¶Single question: ‘In general, would you say your health is poor (1), 
fair (2), good (3), very good (4) or excellent (5)?’
HCTD, Healthcare Task Difficulty; MTBQ, Multimorbidity Treatment 
Burden Questionnaire. 
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Table 5 Characteristics by categories of treatment burden (main study baseline data)
N None (0) Low (<10)
Medium 
(10–22) High (≥22) Unadjusted OR* Adjusted OR† P value
Participants 1524 308 385 425 406
Age (mean) 1524 74 73 71 66 0.96 (0.95 to 0.97) 0.96 (0.95 to 0.97) <0.0001
Gender (n, (%)) 
  Male 651 168 (22) 208 (28) 193 (26) 182 (24) 0.74 (0.62 to 0.88) 0.73 (0.60 to 0.87) 0.001
Number of long-term conditions 
(n,(%)) 
  3 1217 246 (20) 323 (27) 335 (28) 313 (26)
  4 or more 307 62 (20) 62 (20) 90 (29) 93 (30) 1.21 (0.97 to 1.52) 1.38 (1.09 to 1.74) 0.007
Long-term conditions 
(n, (%)) 
  Cardiovascular 
disease
1423 294 (21) 367 (26) 389 (27) 373 (26) 0.62 (0.44 to 0.91) 0.79 (0.54 to 1.14) 0.208
  Stroke/Transient 
ischaemic attack
517 127 (25) 140 (27) 135 (26) 115 (22) 0.69 (0.57 to 0.83) 0.82 (0.67 to 1.01) 0.059
  Diabetes 800 158 (20) 200 (25) 211 (26) 231 (29) 1.13 (0.94 to 1.35) 1.04 (0.87 to 1.26) 0.633
  Chronic kidney 
disease
454 101 (22) 121 (27) 115 (25) 117 (26) 0.86 (0.71 to 1.05) 1.10 (0.89 to 1.36) 0.356
  Chronic 
obstructive 
pulmonary disease 
or asthma
758 148 (20) 185 (24) 222 (29) 203 (27) 1.08 (0.90 to 1.29) 0.91 (0.75 to 1.10) 0.326
  Epilepsy 76 14 (18) 21 (28) 24 (32) 17 (22) 0.94 (0.63 to 1.41) 0.76 (0.50 to 1.17) 0.216
  Atrial fibrillation 524 119 (23) 155 (30) 142 (27) 108 (21) 0.68 (0.56 to 0.82) 0.91 (0.74 to 1.12) 0.369
  Severe mental 
health problems‡
66 7 (11) 10 (15) 17 (26) 32 (48) 2.61 (1.64 to 4.15) 1.75 (1.08 to 2.82) 0.022
  Depression 553 85 (15) 105 (19) 169 (31) 194 (35) 1.92 (1.59 to 2.32) 1.43 (1.16 to 1.77) 0.001
  Dementia 58 14 (24) 10 (17) 12 (21) 22 (38) 1.27 (0.78 to 2.11) 2.26 (1.34 to 3.81) 0.002
  Learning disability 14 2 (14) 2 (14) 6 (43) 4 (29) 1.47 (0.59 to 3.69) 1.07 (0.36 to 3.21) 0.907
  Rheumatoid 
arthritis
102 15 (15) 18 (18) 40 (39) 29 (28) 1.41 (0.99 to 2.01) 1.28 (0.88 to 1.82) 0.202
  Heart failure 154 36 (23) 41 (27) 38 (25) 39 (25) 0.85 (0.63 to 1.14) 1.06 (0.77 to 1.44) 0.340
Age left full-time education (n, (%))§ 
  ≤16 years 681 164 (24) 172 (25) 177 (26) 168 (25) 1.00 (0.99 to 1.01) 1.01 (0.99 to 1.02) 0.450
  England 1078 15 15 15 16 1.01 (1.00 to 1.01) 1.00 (0.99 to 1.01) 0.904
  Scotland 467 26 26 24 24 1.00 (0.99 to 1.01) 0.99 (0.99 to 1.00) 0.032
EuroQol five 
dimensions, five level 
questionnaire (EQ-
5D-5L)11 (mean) 
1520 0.67 0.63 0.56 0.42 0.11 (0.08 to 0.16) 0.09 (0.06 to 0.12) <0.0001
Disease burden 
score12 (mean) 
1443 12.8 15.7 19.0 26.1 1.06 (1.06 to 1.08) 1.07 (1.07 to 1.09) <0.0001
Self-rated health (n, (%)) 
  Poor 315 36 (11) 42 (13) 75 (24) 162 (51)
  Fair 674 112 (17) 168 (25) 216 (32) 178 (26) 0.39 (0.30 to 0.50) 0.41 (0.31 to 0.53) <0.0001
  Good 422 111 (26) 138 (33) 116 (27) 57 (14) 0.20 (0.15 to 0.26) 0.19 (0.14 to 0.26) <0.0001
  Very good 87 40 (46) 28 (32) 16 (18) 3 (3) 0.08 (0.05 to 0.13) 0.08 (0.05 to 0.12) <0.0001
  Excellent 5 3 (60) 2 (40) 0 0 0.04 (0.01 to 0.23) 0.03 (0.00 to 0.16) <0.0001
Continued
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participants with low quality of life (EQ-5D-5L)14 score, 
high disease burden score15 and poor self-rated health 
were more likely to have high treatment burden. We also 
found that female participants were more likely to report 
high treatment burden compared with male participants. 
This has not been reported elsewhere. There was no asso-
ciation between deprivation level and treatment burden 
score. One might expect that people from more deprived 
areas might have fewer support networks and resources 
and so would experience higher treatment burden. Alter-
natively, one could argue that participants from more 
deprived areas might be more accepting of how looking 
after their health impacts on their day-to-day life and so 
report lower treatment burden.
A key strength of this study is that the MTBQ has been 
validated in a large sample of participants for whom it 
is intended—elderly multimorbid patients with a mean 
age of 71 years and three or more long-term conditions. 
In comparison, the English version of the Tran’s TBQ 
was validated in a younger computer-literate population 
with a mean age of 51 years.4 5 The MTBQ had good face 
validity, was found to be user-friendly and fits on a single 
page of A4 paper in size 14 font. All aspects of treatment 
burden identified in a comprehensive evidence-based 
framework are included in the questionnaire. In compar-
ison, the most comprehensive existing questionnaire, 
the PETS questionnaire,8 includes 48 questions and is 
time-consuming to complete, and several of the other 
existing questionnaires focus on only some aspects of 
treatment burden.6 7 Preliminary assessment of respon-
siveness found that, as expected, a positive change in 
both quality of life (EQ-5D-5L)14 score and patient-cen-
tred care (PACIC)16 score between baseline and 9-month 
follow-up was associated with a reduction in treatment 
burden (MTBQ) score. Of the other relevant PROMs, 
only the HCTD has been assessed for responsiveness,6 
but the HCTD addresses fewer topics and has a narrower 
range of response options, possibly contributing to its 
greater problems with skewness and floor effects.
A limitation of this study is that the MTBQ was devel-
oped using a framework of treatment burden developed 
from qualitative study in the USA.1 However, apart from 
the issue of paying for care, we felt that other domains of 
treatment burden were likely to be generalisable, and we 
wanted to develop a measure that covered generic issues 
that would be relevant in a range of settings rather than 
specific to one healthcare system. Our measure was also 
informed by qualitative papers from different countries 
(including the UK) to ensure we included the important 
concepts.10–12 In cognitive interviews, participants with 
multimorbidity felt that the questionnaire captured the 
range of factors that contribute to treatment burden.
A further limitation is that the participants of this study 
were recruited into a trial, which creates potential for 
selection bias and may limit generalisability. However, 
the trial participants had similar characteristics to those 
invited but declining participation in respect of age, 
gender, number and type of long-term conditions (data 
will be reported with the 3D trial results). Almost all the 
participants of this study were white British and further 
work is planned to validate the questionnaire in other 
populations. We found high floor effects with 22% of 
participants scoring a global MTBQ score of 0. All of 
the other treatment burden measures also show simi-
larly high floor effects.4–8 One explanation for this is a 
‘response shift’, whereby patients adapt their everyday 
life so that looking after their health conditions becomes 
more acceptable to them over time and causes less 
perceived burden.23 The following are the implications of 
positively skewed treatment burden scores and high floor 
effects: first, this can make it difficult to detect change 
(ie, it is not possible to improve from a treatment burden 
score of 0); and second, mean treatment burden scores 
should be interpreted with caution. Preliminary anal-
ysis of responsiveness, however, has shown that changes 
in MTBQ score correlate as expected with changes in 
quality of life (EQ-5D-5L)14 score and patient-centred 
care (PACIC)16 over time. We recommend that, due to 
the skewness of global MTBQ scores, researchers should 
report the median and IQR rather than the mean and SD, 
and report the proportion of patients with high, medium, 
low or no treatment burden (MTBQ scores ≥22, 10–22, 
<10 and 0, respectively).
The MTBQ scale is a concise measure of treatment 
burden for patients with multimorbidity that has demon-
strated good content validity, construct validity, internal 
consistency reliability and responsiveness. It is a useful 
research tool for assessing the impact of interventions on 
treatment burden for patients with multimorbidity. We 
anticipate the scale being used alongside other measures, 
such as disease burden, and that findings from the two 
measures will be related. The MTBQ could also be used 
in clinical practice to highlight problem areas for patients 
with multimorbidity, such as difficulties the patient may 
N None (0) Low (<10)
Medium 
(10–22) High (≥22) Unadjusted OR* Adjusted OR† P value
*Ordinal logistic regression comparing no burden (0), low burden (<10), medium burden (10–22) and high burden (≥22).
†Ordinal logistic regression comparing no burden (0), low burden (<10), medium burden (10–22) and high burden (≥22), adjusted for age, 
gender, number of comorbidities, age left full-time education and individual deprivation score.
‡Including schizophrenia and psychotic illness.
§Individual Index of Multiple Deprivation score, 2010, for England, and Scottish Index of Multiple Deprivation score, 2010, for Scotland, for 
both a higher score correlates with greater deprivation.
Statistically significant associations are shown in bold
Table 5 Continued 
 o
n
 24 April 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019413 on 12 April 2018. Downloaded from 
10 Duncan P, et al. BMJ Open 2018;8:e019413. doi:10.1136/bmjopen-2017-019413
Open Access 
have with their medication or with making recommended 
lifestyle changes. Further work is needed to validate the 
MTBQ for use in a clinical setting.
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